Date: 2017-05-16
Type of information: Private placement
Company: Conatus Pharmaceuticals (USA - CA)
Investors:
Amount: $30.6 million
Funding type: private placement
Planned used:
- Conatus intends to use approximately $19.4 million of the net proceeds from the offering to fund pipeline expansion and for working capital and other general corporate purposes. Conatus used approximately $11.2 million of the net proceeds to repurchase and retire 2,166,836 shares of common stock held by funds affiliated with Advent Private Equity at a price equal to the net proceeds per share that Conatus received from this offering, before expenses.
Others:
- • On May 16, 2017, Conatus Pharmaceuticals announced the completion of an underwritten public offering of 5,980,000 shares of its common stock, including 780,000 shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares. All shares in the offering were sold by Conatus at a price to the public of $5.50 per share.
- Net proceeds from the offering, after deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $30.6 million.
- • On May 11, 2017, Conatus Pharmaceuticals announced that it has priced an underwritten public offering of 5,200,000 shares of its common stock at a price to the public of $5.50 per share. Gross proceeds, before underwriting discounts and commissions and estimated offering costs, are expected to be approximately $28.6 million.
Conatus has granted the underwriters a 30-day option to purchase up to 780,000 additional shares of its common stock. The offering is expected to close on or about May 16, 2017, subject to satisfaction of customary closing conditions.
- • On May 10, 2017, Conatus Pharmaceuticals announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Conatus also expects to grant to the underwriters for the offering a 30-day option to purchase an additional 15% of the shares of common stock offered in the public offering. All of the shares to be sold in the offering are to be sold by Conatus.
Stifel and SunTrust Robinson Humphrey are acting as book-running managers for the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Therapeutic area: Hepatic diseases - Liver diseases
Is general: Yes
